Agency Information Collection Activities; Proposed Collection; Public Comment Request; Extension of a Currently Approved Information Collection (ICR-REV); Centers for Independent Living Annual Performance Report (CILPPR); Correction, 12610-12611 [2017-04169]
Download as PDF
12610
Federal Register / Vol. 82, No. 42 / Monday, March 6, 2017 / Notices
Studies where differences in potassium
intake or values are confounded with
alteration of other nutrient levels will be
excluded.
IV. Outcomes
V. Timing
A. Studies reporting exclusively on
kidney stone formation need to follow
participants for at least five years,
studies reporting exclusively on kidney
disease need to follow participants for at
least two years, studies reporting
exclusively on cardiovascular disease or
stroke need to follow patients for at least
12 months; all other studies need to
report on an exposure period of at least
four weeks to be eligible.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
VI. Setting
A. Studies in community-dwelling
participants will be eligible.
VII. Study Design
A. Prospective cohort studies and
nested case-control studies, where at
least two groups are compared based on
measured potassium intake or
biomarker values will be eligible.
Retrospective studies, case series, cross-
19:24 Mar 03, 2017
Sharon B. Arnold,
Acting AHRQ Director.
[FR Doc. 2017–04193 Filed 3–3–17; 8:45 am]
A. Studies reporting on mortality (allcause, CVD, CHD, or renal);
cardiovascular disease morbidity,
including coronary heart disease (CHD),
acute coronary syndrome (unstable
angina and myocardial infarction),
stroke, myocardial infarction (STsegment elevation myocardial infarction
[STEMI] and non-ST elevation
myocardial infarction [NSTEMI]),
requiring coronary revascularization
procedures (angioplasty, coronary stent
placement, coronary artery bypass),
other atherosclerotic revascularization
procedures (carotid endarterectomy),
left ventricular hypertrophy,
hospitalization for heart failure, or
hospitalization for any cause of
coronary heart disease or cardiovascular
disease, or combined CVD morbidity
and mortality; or reporting on renal
function intermediary and clinical
outcomes including creatinine clearance
(CrCl), serum creatinine (SCr),
glomerular filtration rate (GFR), end
stage renal disease, chronic kidney
disease (CKD), albuminuria/proteinuria
(including urine albumin-to-creatinine
ratio, urine albumin dipstick level,
urine protein-to-creatinine ratio,
albumin excretion rate), kidney stone
incidence, or acute kidney injury will be
eligible. Studies that do not report
baseline data on the outcomes of
interest will be excluded.
VerDate Sep<11>2014
sectional studies or surveys, and case
reports will be excluded.
Jkt 241001
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Administration on Intellectual and
Developmental Disabilities, President’s
Committee for People With Intellectual
Disabilities
Administration for Community
Living, HHS.
ACTION: Notice.
AGENCY:
Thursday, March 23, 2017 from
8:30 a.m. to 5:00 p.m.; and Friday,
March 24, 2017 from 9:00 a.m. to 3:00
p.m.
These meetings will be open to the
general public.
ADDRESSES: These meetings will be held
in U.S. Department of Health and
Human Services/Hubert H. Humphrey
Building located at 200
IndependenceAvenue SW., Conference
Room 705A, Washington, DC 20201.
Individuals who would like to
participate via conference call may do
so by dialing toll-free #: 1–800–779–
4694, when prompted enter pass code:
4511687. Individuals whose full
participation in the meeting will require
special accommodations (e.g., sign
language interpreting services, assistive
listening devices, materials in
alternative format such as large print or
Braille) should notify Ms. Allison Cruz,
Director, Office of Innovation, via email
at Allison.Cruz@acl.hhs.gov, or via
telephone at 202–795–7334, no later
than Monday, March 6, 2017. The
PCPID will attempt to accommodate
requests made after this date, but cannot
guarantee the ability to grant requests
received after the deadline. All meeting
sites are barrier free, consistent with the
Americans with Disabilities Act (ADA)
and the Federal Advisory Committee
Act (FACA).
AGENDA: The Committee Members will
discuss preparation of the PCPID 2017
Report to the President, including its
content and format, and related data
collection and analysis required to
complete the writing of the Report.
ADDITIONAL INFORMATION: For further
information, please contact Ms. Allison
Cruz, Director, Office of Innovation, 330
C Street SW., Switzer Building, Room
1114, Washington, DC 20201.
DATES:
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
Telephone: 202–795–7334. Fax: 202–
795–7334. Email: Allison.Cruz@
acl.hhs.gov.
SUPPLEMENTARY INFORMATION: The
PCPID acts in an advisory capacity to
the President and the Secretary of
Health and Human Services on a broad
range of topics relating to programs,
services and support for individuals
with intellectual disabilities. The PCPID
executive order stipulates that the
Committee shall: (1) Provide such
advice concerning intellectual
disabilities as the President or the
Secretary of Health and Human Services
may request; and (2) provide advice to
the President concerning the following
for people with intellectual disabilities:
(A) Expansion of educational
opportunities; (B) promotion of
homeownership; (C) assurance of
workplace integration; (D) improvement
of transportation options; (E) expansion
of full access to community living; and
(F) increasing access to assistive and
universally designed technologies.
Dated: February 27, 2017.
Bob Williams,
Acting Designated Federal Official, PCPID,
Administration on Disabilities (AoD).
[FR Doc. 2017–04165 Filed 3–3–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request; Extension of a
Currently Approved Information
Collection (ICR–REV); Centers for
Independent Living Annual
Performance Report (CILPPR);
Correction
Independent Living
Administration, Administration for
Community Living, HHS.
ACTION: Notice of correction.
AGENCY:
The Administration for
Community Living published a
proposed collection of information
document in the Federal Register on
February 23, 2017. (82 FR 11471 and
11472) The document contained an
incorrect date and email address. In
addition under the heading ‘‘New
Requirements’’, the first paragraph was
revised.
FOR FURTHER INFORMATION CONTACT:
Corinna Styles, 202–795–7446.
Corrections:
Under the DATES section, page 11471,
column two, correct the notice to read:
‘‘Submit written or electronic comments
SUMMARY:
E:\FR\FM\06MRN1.SGM
06MRN1
Federal Register / Vol. 82, No. 42 / Monday, March 6, 2017 / Notices
on the collection of information by May
5, 2017.’’
Under the ADDRESSES section, page
11471, column two, correct the notice to
read: ‘‘Submit electronic comments on
the collection of information to:
cilpprcomments@acl.hhs.gov’’.
Under the heading ‘‘New
Requirements’’, the first paragraph, page
11472, column one, replace the first
paragraph with the following paragraph
below:
‘‘The Workforce Innovation and
Opportunity Act (WIOA), enacted on July 22,
2014, added a new core service to the list of
‘‘independent living core services’’ that ACL
funded Centers for Independent Living (CILs)
are required to provide. Prior to WIOA, CILs
were required to provide the following core
services: (1) Information and referral services;
(2) independent living skills training; (3) peer
counseling, including cross-disability peer
counseling; (4) and individual and systems
advocacy. WIOA added additional
‘‘transition and diversion’’ core services
comprised of three components. It requires
CILs to:’’.
Dated: February 24, 2017.
Daniel P. Berger,
Acting Administrator and Assistant Secretary
for Aging.
[FR Doc. 2017–04169 Filed 3–3–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2017–N–0136]
Public Meeting on Patient-Focused
Drug Development for Autism;
Request for Comments
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA, the Agency, or
we) is announcing a public meeting and
an opportunity for public comment on
Patient-Focused Drug Development for
autism. Patient-Focused Drug
Development is part of FDA’s
performance commitments made as part
of the fifth authorization of the
Prescription Drug User Fee Act (PDUFA
V). The public meeting is intended to
allow FDA to obtain patient
perspectives on the impact of autism on
daily life as well as patient views on
treatment approaches for autism.
DATES: The public meeting will be held
on May 4, 2017, from 1 p.m. to 5 p.m.
Registration to attend the meeting must
be received by April 24, 2017 (see
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:24 Mar 03, 2017
Jkt 241001
The public meeting will be
held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993–0002.
Entrance for the public meeting
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
performed. For more information on
parking and security procedures, please
refer to https://www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
You may submit comments as
follows:
ADDRESSES:
Electronic Submissions
Food and Drug Administration
AGENCY:
SUPPLEMENTARY INFORMATION for
instructions). Submit either electronic
or written comments on the public
meeting by July 5, 2017. Late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before July 5, 2017. The https://
www.regulations.gov electronic filing
system will accept comments until
midnight Eastern Time at the end of July
5, 2016. Comments received by mail/
hand delivery/courier (for written paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date. See the SUPPLEMENTARY
INFORMATION section for registration date
and information.
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
12611
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–0136 for ‘‘Public Meeting on
Patient-Focused Drug Development for
Autism.’’ Received comments, those
filed in a timely manner (see DATES),
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
E:\FR\FM\06MRN1.SGM
06MRN1
Agencies
[Federal Register Volume 82, Number 42 (Monday, March 6, 2017)]
[Notices]
[Pages 12610-12611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04169]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Agency Information Collection Activities; Proposed Collection;
Public Comment Request; Extension of a Currently Approved Information
Collection (ICR-REV); Centers for Independent Living Annual Performance
Report (CILPPR); Correction
AGENCY: Independent Living Administration, Administration for Community
Living, HHS.
ACTION: Notice of correction.
-----------------------------------------------------------------------
SUMMARY: The Administration for Community Living published a proposed
collection of information document in the Federal Register on February
23, 2017. (82 FR 11471 and 11472) The document contained an incorrect
date and email address. In addition under the heading ``New
Requirements'', the first paragraph was revised.
FOR FURTHER INFORMATION CONTACT: Corinna Styles, 202-795-7446.
Corrections:
Under the DATES section, page 11471, column two, correct the notice
to read: ``Submit written or electronic comments
[[Page 12611]]
on the collection of information by May 5, 2017.''
Under the ADDRESSES section, page 11471, column two, correct the
notice to read: ``Submit electronic comments on the collection of
information to: cilpprcomments@acl.hhs.gov''.
Under the heading ``New Requirements'', the first paragraph, page
11472, column one, replace the first paragraph with the following
paragraph below:
``The Workforce Innovation and Opportunity Act (WIOA), enacted
on July 22, 2014, added a new core service to the list of
``independent living core services'' that ACL funded Centers for
Independent Living (CILs) are required to provide. Prior to WIOA,
CILs were required to provide the following core services: (1)
Information and referral services; (2) independent living skills
training; (3) peer counseling, including cross-disability peer
counseling; (4) and individual and systems advocacy. WIOA added
additional ``transition and diversion'' core services comprised of
three components. It requires CILs to:''.
Dated: February 24, 2017.
Daniel P. Berger,
Acting Administrator and Assistant Secretary for Aging.
[FR Doc. 2017-04169 Filed 3-3-17; 8:45 am]
BILLING CODE 4154-01-P